Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function

Mei Zhou, Liming Zhang

Department of Hematology, Zhuji Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province 311800, China;

For correspondence:- Liming Zhang Email: lianzhang4194@126.com Tel:+8613777338978

Accepted: 28 April 2022 Published: 31 March 2022

Citation: Zhou M, Zhang L. Efficacy of imatinib mesylate in combination with radiotherapy in acute leukemia, and the effect on immune function. Trop J Pharm Res 2022; 21(5):1117-1123 doi: 10.4314/tjpr.v21i5.29

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the clinical efficacy of imatinib mesylate plus radiotherapy for the treatment of acute leukemia and its effect on immune function.

Methods: A retrospective study was conducted on 88 patients with acute leukemia admitted to Zhuji Affiliated Hospital of Shaoxing University between July 2017 and July 2021. They were assigned (randomly, 1:1) to a control group (radiotherapy) or a study group (imatinib mesylate plus radiotherapy) according to different treatment regimens. Outcome measures assessed included the clinical efficacy of the treatments in the patients and their immune functions.

Results: The two groups did not show any significant differences with regard to general patient profiles. After treatment, both groups presented reduced white blood cell (WBC) and platelet count (PLT) and elevated red blood cells count (RBC). The level of hemoglobin (Hb) level showed a slight decline in the control group but a significant increase in the study group (p < 0.05). The study group showed better improvement in the levels of WBC, PLT, RBC, and Hb than the control group (p < 0.05). The absolute values of peripheral blood mature neutrophils decreased in both groups after treatment, down to the lowest level at week 2, but rebounded, with higher absolute values in the study group at weeks 2, 3, and 4 of treatment (p < 0.05). Imatinib mesylate plus radiotherapy was associated with higher efficacy, compared with radiotherapy alone (p < 0.05).

Conclusion: Radiotherapy plus imatinib mesylate effectively enhances the immune functions of acute leukemia patients, mitigates inflammatory responses, alleviates clinical symptoms, and boosts clinical efficacy. Further clinical trials are, however, required prior to general application in clinical practice.

Keywords: Acute leukemia, Immune functions, Radiotherapy, Imatinib mesylate